This study is looking at treatments for prostate cancer in men aged 18 and older. It's testing Stereotactic Body Radiotherapy (SBRT), a standard radiation treatment, either alone or combined with Relugolix (Orgovyx), an oral medication. Relugolix is taken once a day for 30 days. Participants will be randomly assigned to receive one of these treatments. The main goal is to see if combining SBRT with Relugolix leads to a better prostate-specific antigen (PSA) nadir (the lowest point your PSA reaches after treatment) compared to SBRT alone. We also want to see if this combination is better for sexual and hormonal function. The study plans to enroll 60 participants, but its current status is unclear.

Study design

This is an interventional study where participants will be randomly assigned to receive either SBRT alone or SBRT combined with Relugolix. It plans to enroll 60 participants.

What's involved

Participants will take Relugolix orally once daily for 30 days if assigned to that group, and will receive SBRT radiation treatment.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome, PSA nadir, will be measured for up to 2 years after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.